Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20766759 | 1.00 | POLG (0.54) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL22678647 | 1.00 | POLG (0.54) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL29664935 | 0.98 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL24782133 | 0.90 | LMNA (0.46) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL24512478 | 0.90 | LMNA (0.46) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL29664879 | 0.85 | NT5E (0.50) | P2RY2POLB | |
| SCHEMBL29664852 | 0.84 | POLG (0.48) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL29664912 | 0.82 | POLG (0.45) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL24512479 | 0.80 | POLG (0.61) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18573821 | 0.80 | POLG (0.53) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279728-B2 | Broad spectrum viral inhibitor | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200361982-A1 | BROAD SPECTRUM VIRAL INHIBITOR | THE PENN STATE RESEARCH FOUNDATION | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279728-B2 | Broad spectrum viral inhibitor | DPP4, TREH, DPP8 | POLG 4082/4885P2RY2 3431/4885P2RY4 2183/4885 |
| US-20200361982-A1 | BROAD SPECTRUM VIRAL INHIBITOR | DPP4, TREH, DPP8 | POLG 4082/4885P2RY2 3431/4885P2RY4 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.